ClinicalTrials.gg
CompletedNCT00542997Updated Sep 1, 2011Results posted

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

A Phase 3 interventional study of Human Normal Immunoglobulin for Subcutaneous Administration (IGSC) in Common Variable Immunodeficiency, X-linked Agammaglobulinemia and Autosomal Recessive Agammaglobulinemia, sponsored by CSL Behring. Completed at 19 sites in 9 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-09-01.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
2 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).

Read the detailed description

This study consisted of a 12-week wash-in/wash-out period followed by a 28-week efficacy period. During the 28-week efficacy period, subjects visited the study site at least every 4 weeks for efficacy and safety evaluations and additionally recorded details regarding IgPro20 dose and certain aspects of efficacy and safety in a diary. Pharmacokinetic (PK) parameters were assessed in a sub-group of subjects during 1 treatment interval at steady-state (Week 28 ± 1).

02

Conditions studied

  • Common Variable Immunodeficiency
  • X-linked Agammaglobulinemia
  • Autosomal Recessive Agammaglobulinemia

Keywords

  • Subcutaneous immune globulin
  • SCIG
03

In context

Common Variable Immunodeficiency

54 studies on the registry are indexed under Common Variable Immunodeficiency; 13 are open to participants now.

This study's enrollment of 51 is above the median of 40 across 39 interventional studies indexed under Common Variable Immunodeficiency.

Browse Common Variable Immunodeficiency studies →

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with primary humoral immunodeficiency, namely with a diagnosis of Common Variable Immunodeficiency (CVID) as defined by the Pan-American Group for Immunodeficiency (PAGID) and European Society for Immunodeficiencies (ESID), X-linked agammaglobulinemia (XLA) as defined by PAGID and ESID, or Autosomal Recessive Agammaglobulinemia
  • Chest X-ray or CT scan obtained within 1 year prior to enrolment

Exclusion criteria

Exclusion Criteria:

  • Newly diagnosed PID, i.e. subjects who have not previously received immunoglobulin replacement therapy
  • Ongoing serious bacterial infection at the time of screening
  • of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma and immunodeficiency with thymoma
  • Allergic or other severe reactions to immunoglobulins or other blood products associated with high anti-IgA

Additional criteria may apply and examination by an investigator is required to determine eligibility.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    IgPro20

    Biological: Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)

Interventions

  • IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.

    Also known as: Hizentra, SCIG

06

What researchers measure

Primary outcomes

  1. Total Serum IgG Trough Levels

    Total IgG trough levels for IgPro20 treatment at steady state were compared with documented trough level data for IgG treatment received prior to enrolling in the study (either subcutaneous or intravenous IgG). For this purpose, 6 consecutive IgPro20 trough values (obtained prior to infusions 12 to 17) per subject were aggregated to the subject's median value and then median values across subjects were summarised using descriptive statistics. The same procedure was applied to pre-study treatment using the 3 most recent IgG trough values ≥ 5 g/L obtained prior to the first IgPro20 infusion.

    Time frame: Up to 6 months prior to first IgPro20 treatment (Pre-study treatment) and Week 12 to 17 (IgPro20 treatment)

Secondary outcomes

  1. Annual Rate of Clinically Documented Serious Bacterial Infections (ITT Population)

    Serious bacterial infections (SBIs) included bacterial pneumonia, bacteraemia/septicaemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. Diagnosis of the SBIs was based on the presence of predefined clinical signs and symptoms as well as on laboratory parameters. The annual rate was calculated based on the total number of SBIs and the total number of study days during the efficacy period for all subjects in the ITT population and adjusted to 365 days.

    Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit

  2. Annual Rate of Clinically Documented Serious Bacterial Infections (PPE Population)

    Serious bacterial infections (SBIs) included bacterial pneumonia, bacteraemia/septicaemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. Diagnosis of the SBIs was based on the presence of predefined clinical signs and symptoms as well as on laboratory parameters. The annual rate was calculated based on the total number of SBIs and the total number of study days during the efficacy period for all subjects in the PPE population and adjusted to 365 days.

    Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit

  3. Annual Rate of Infection Episodes

    The annual rate of episodes was calculated based on the total number of any infection type and the total number of study days during the efficacy period for all subjects in the ITT population and adjusted to 365 days.

    Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit

  4. Annual Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections

    The annual rate was calculated based on the total number of days out of work/school/kindergarten/day care or unable to perform normal activities due to infections in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.

    Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit

  5. Annual Rate of the Number of Days of Hospitalization Due to Infections

    The annual rate was calculated based on the total number of days of hospitalization due to infections in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.

    Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit

  6. Annual Rate of Antibiotic Use for Infection Prophylaxis and Treatment

    The annual rate was calculated based on the total number of days of antibiotic use in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.

    Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit

Other outcomes

  1. Maximum Concentration (Cmax) of Total Serum IgG

    Time frame: Week 28 (±1week)

  2. Timepoint of Maximum Concentration (Tmax) of Total Serum IgG

    Time frame: Week 28 (±1week)

  3. Area Under the Concentration-Time Curve (AUC_last) of Total Serum IgG

    AUC_last = Area under the concentration-time curve until last measured concentration.

    Time frame: Week 28 (±1week)

  4. Area Under the Concentration-Time Curve (AUCτ) of Total Serum IgG

    AUCτ = Area under the concentration-time curve during regular dosing interval;

    Time frame: Week 28 (±1week)

07

Results

Posted Mar 15, 2011

Participant flow

This multinational study enrolled subjects at 15 of the participating study centers in Europe.

Wash in / Wash Out Period
Participant flow — Wash in / Wash Out Period
MilestoneIgPro20 (All Treated)
Started51
Completed46
Not completed5
Withdrew: Withdrawal by subject2
Withdrew: Adverse event3
Efficacy Period
Participant flow — Efficacy Period
MilestoneIgPro20 (All Treated)
Started46
Completed43
Not completed3
Withdrew: Adverse event3

Outcome measures

PrimaryTotal Serum IgG Trough Levels

Total IgG trough levels for IgPro20 treatment at steady state were compared with documented trough level data for IgG treatment received prior to enrolling in the study (either subcutaneous or intravenous IgG). For this purpose, 6 consecutive IgPro20 trough values (obtained prior to infusions 12 to 17) per subject were aggregated to the subject's median value and then median values across subjects were summarised using descriptive statistics. The same procedure was applied to pre-study treatment using the 3 most recent IgG trough values ≥ 5 g/L obtained prior to the first IgPro20 infusion.

Time frame:
Up to 6 months prior to first IgPro20 treatment (Pre-study treatment) and Week 12 to 17 (IgPro20 treatment)
Reported as:
Mean · g/L
Total Serum IgG Trough Levels
g/LIgPro20Pre-study IgG Treatment
Total Serum IgG Trough Levels8.10 ± 1.447.49 ± 1.57
SecondaryAnnual Rate of Clinically Documented Serious Bacterial Infections (ITT Population)

Serious bacterial infections (SBIs) included bacterial pneumonia, bacteraemia/septicaemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. Diagnosis of the SBIs was based on the presence of predefined clinical signs and symptoms as well as on laboratory parameters. The annual rate was calculated based on the total number of SBIs and the total number of study days during the efficacy period for all subjects in the ITT population and adjusted to 365 days.

Time frame:
Efficacy period: week 12 to week 40 after study start or to the completion visit
Reported as:
Number · SBIs/subject/year
Annual Rate of Clinically Documented Serious Bacterial Infections (ITT Population)
SBIs/subject/yearIgPro20
Annual Rate of Clinically Documented Serious Bacterial Infections (ITT Population)0
SecondaryAnnual Rate of Clinically Documented Serious Bacterial Infections (PPE Population)

Serious bacterial infections (SBIs) included bacterial pneumonia, bacteraemia/septicaemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. Diagnosis of the SBIs was based on the presence of predefined clinical signs and symptoms as well as on laboratory parameters. The annual rate was calculated based on the total number of SBIs and the total number of study days during the efficacy period for all subjects in the PPE population and adjusted to 365 days.

Time frame:
Efficacy period: week 12 to week 40 after study start or to the completion visit
Reported as:
Number · SBIs/subject/year
Annual Rate of Clinically Documented Serious Bacterial Infections (PPE Population)
SBIs/subject/yearIgPro20
Annual Rate of Clinically Documented Serious Bacterial Infections (PPE Population)0
SecondaryAnnual Rate of Infection Episodes

The annual rate of episodes was calculated based on the total number of any infection type and the total number of study days during the efficacy period for all subjects in the ITT population and adjusted to 365 days.

Time frame:
Efficacy period: week 12 to week 40 after study start or to the completion visit
Reported as:
Number · episodes/subject/year
Annual Rate of Infection Episodes
episodes/subject/yearIgPro20
Annual Rate of Infection Episodes5.18 (4.31 to 6.17)
SecondaryAnnual Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections

The annual rate was calculated based on the total number of days out of work/school/kindergarten/day care or unable to perform normal activities due to infections in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.

Time frame:
Efficacy period: week 12 to week 40 after study start or to the completion visit
Reported as:
Number · days/subject/year
Annual Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections
days/subject/yearIgPro20
Annual Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections8.00
SecondaryAnnual Rate of the Number of Days of Hospitalization Due to Infections

The annual rate was calculated based on the total number of days of hospitalization due to infections in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.

Time frame:
Efficacy period: week 12 to week 40 after study start or to the completion visit
Reported as:
Number · days/subject/year
Annual Rate of the Number of Days of Hospitalization Due to Infections
days/subject/yearIgPro20
Annual Rate of the Number of Days of Hospitalization Due to Infections3.48
SecondaryAnnual Rate of Antibiotic Use for Infection Prophylaxis and Treatment

The annual rate was calculated based on the total number of days of antibiotic use in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.

Time frame:
Efficacy period: week 12 to week 40 after study start or to the completion visit
Reported as:
Number · days/subject/year
Annual Rate of Antibiotic Use for Infection Prophylaxis and Treatment
days/subject/yearIgPro20
Annual Rate of Antibiotic Use for Infection Prophylaxis and Treatment72.75
Other pre-specifiedMaximum Concentration (Cmax) of Total Serum IgG
Time frame:
Week 28 (±1week)
Reported as:
Mean · g/L
Maximum Concentration (Cmax) of Total Serum IgG
g/LIgPro20 (PK Substudy)
Maximum Concentration (Cmax) of Total Serum IgG8.26 ± 1.25
Other pre-specifiedTimepoint of Maximum Concentration (Tmax) of Total Serum IgG
Time frame:
Week 28 (±1week)
Reported as:
Median · day
Timepoint of Maximum Concentration (Tmax) of Total Serum IgG
dayIgPro20 (PK Substudy)
Timepoint of Maximum Concentration (Tmax) of Total Serum IgG2.06 (0.94 to 6.92)
Other pre-specifiedArea Under the Concentration-Time Curve (AUC_last) of Total Serum IgG

AUC_last = Area under the concentration-time curve until last measured concentration.

Time frame:
Week 28 (±1week)
Reported as:
Mean · day x g/L
Area Under the Concentration-Time Curve (AUC_last) of Total Serum IgG
day x g/LIgPro20 (PK Substudy)
Area Under the Concentration-Time Curve (AUC_last) of Total Serum IgG53.70 ± 9.16
Other pre-specifiedArea Under the Concentration-Time Curve (AUCτ) of Total Serum IgG

AUCτ = Area under the concentration-time curve during regular dosing interval;

Time frame:
Week 28 (±1week)
Reported as:
Mean · day x g/L
Area Under the Concentration-Time Curve (AUCτ) of Total Serum IgG
day x g/LIgPro20 (PK Substudy)
Area Under the Concentration-Time Curve (AUCτ) of Total Serum IgG53.61 ± 9.98

Adverse events

Collected over The observation period for adverse events was from the time the subjects had given informed consent until they had the final examination (completion visit up to 40 weeks) or extended when serious adverse events were reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IgPro20 (All Treated)—5/51 (9.8%)50/51 (98%)
Most frequent serious events
Most frequent serious events
EventIgPro20 (All Treated)
DiarrhoeaGastrointestinal disorders1/51
PneumoniaInfections and infestations1/51
PyrexiaGeneral disorders1/51
BronchiolitisInfections and infestations1/51
AppendicitisInfections and infestations1/51
SciaticaNervous system disorders1/51
Most frequent other events
Showing 10 of 31
Most frequent other events
EventIgPro20 (All Treated)
BronchitisInfections and infestations16/51
PyrexiaGeneral disorders14/51
CoughRespiratory, thoracic and mediastinal disorders13/51
HeadacheNervous system disorders13/51
NasopharyngitisInfections and infestations12/51
Upper respiratory tract infectionInfections and infestations12/51
DiarrhoeaGastrointestinal disorders10/51
Injection site reactionGeneral disorders9/51
SinusitisInfections and infestations7/51
Injection site painGeneral disorders6/51

Baseline characteristics

Age Continuous
Age Continuous(years)IgPro20 (All Treated)
Mean22.6 ± 16.02
Age, Customized
Age, Customized(Participants)IgPro20 (All Treated)
2 to < 12 years18
12 to < 16 years5
16 to < 65 years28
Sex: Female, Male
Sex: Female, Male(Participants)IgPro20 (All Treated)
Female16
Male35
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IgPro20 (All Treated)
White51
Type of Primary Immunodeficiency
Type of Primary Immunodeficiency(Participants)IgPro20 (All Treated)
Common variable immunodeficiency (CVID)30
X-linked agammaglobulinemia (XLA)20
Autosomal recessive agammaglobulinemia (ARAG)1
08

Study locations

19 sites
  • Study site
    Paris, 75743, France
  • Study site
    Berlin, 13353, Germany
  • Study site
    Düsseldorf, 40001, Germany
  • Study site
    Freiburg, 79095, Germany
  • Study site
    Hannover, 30625, Germany
  • Study site
    Leipzig, 04129, Germany
  • Study site
    Mainz, 55131, Germany
  • Study site
    Munich, 80337, Germany
  • Study site
    Brescia, 25123, Italy
  • Study site
    Warsaw, 04-736, Poland
  • Study site
    Bucharest, 020393, Romania
  • Study site
    Cluj-Napoca, 400162, Romania
  • Study site
    Timisoara, 300011, Romania
  • Study site
    Barcelona, 08036, Spain
  • Study site
    Sevilla, 41013, Spain
  • Study site
    Göteborg, 41685, Sweden
  • Study site
    Berne, 3010, Switzerland
  • Study site
    Cardiff, CF 14 4XW, United Kingdom
  • Study site
    London, NW3 2QG, United Kingdom
09

References and documents

Publications

  • Jolles S, Bernatowska E, de Gracia J, Borte M, Cristea V, Peter HH, Belohradsky BH, Wahn V, Neufang-Huber J, Zenker O, Grimbacher B. Efficacy and safety of Hizentra((R)) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011 Oct;141(1):90-102. doi: 10.1016/j.clim.2011.06.002. Epub 2011 Jun 12. PubMed 21705277 ↗
  • Borte M, Pac M, Serban M, Gonzalez-Quevedo T, Grimbacher B, Jolles S, Zenker O, Neufang-Hueber J, Belohradsky B. Efficacy and safety of hizentra(R), a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol. 2011 Oct;31(5):752-61. doi: 10.1007/s10875-011-9557-z. Epub 2011 Jun 15. PubMed 21674136 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2007
First posted
Oct 12, 2007
Start
Sep 2007
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Mar 15, 2011
Last update
Sep 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00542997
Lead sponsor
CSL Behring
First posted
Oct 12, 2007
Start date
Sep 2007
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Mar 15, 2011
Last update
Sep 1, 2011

Study contacts

Stephen Jolles, MD
principal investigator · University Hospital of Wales, Cardiff, UK

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hizentra

Start the discussion